Effectiveness of Clopidogrel vs Alternative P2Y₁₂ Inhibitors Based on the ABCD-GENE Score.

ABSTRACT:

Background

An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear.

Objectives

The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y₁₂ inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI).

Methods

A total of 4,335 patients who underwent PCI, CYP2C19 genotyping, and P2Y₁₂ inhibitor treatment were included. The primary outcome was major atherothrombotic events (MAE) within 1 year after PCI. Cox regression was performed to assess event risk in clopidogrel-treated (r

SUBMITTER: Thomas CD 

PROVIDER: S-EPMC11074948 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature